Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ATHX-NEWS-pré market up 20 %
ATHX-NEWS-pré market up 20 %
ATHX-NEWS-pré market up 20 %
up 20 % on news
ATHX-GREAT NEWS!! Healios and Athersys Enter Into Regenerative Medicine Partnership for Treatment of Stroke Using MultiStem® Therapy
Date : 01/08/2016 @ 11:00AM
ATHX-GREAT NEWS ! Healios and Athersys Enter Into Regenerative Medicine Partnership for Treatment of Stroke Using MultiStem® Therapy
Date : 01/08/2016 @ 11:00AM
Healios and Athersys Enter Into Regenerative Medicine Partnership for Treatment of Stroke Using MultiStem® Therapy
Date : 01/08/2016 @ 11:00AM- ATHX
Great news today!!!ATHX
yeah, whats up?
yess,reverse 10000-1
looks like bkmp is not dead.....
Subject: your shares BLACKOUT MEDIA-PFD SHS Code effect: ISIN US09250L2007 number: 61.433.330.000 Exchange BLACKOUT MEDIA-PFD SHS Dear client, BLACKOUT MEDIA CORP PFD has decided the shares BLACKOUT MEDIA-PFD SHS. I against issuing 10,000 shares will receive 1 share BLACKOUT MEDIA CORP PFD (ISIN US09250L9788).
Payment date: 07/07/2015 This conversion will be carried out by our services.
This message is sent to you for informational purposes only, you do not need take no action. If you have any questions, please do not hesitate to contact us
thks for that.
looks good up 4% for now- ATHX
ICBU within a year $ 1!!
looks good to us longs...thks.
CBAI---volume 1487512---0.0040---+5%
ICBU--volume 884217--0.0023---up 15%
ICBU---volume 1366296---0.0023---down 18%
premarket 1,62....uchh
CBAI--0.0038---volume 2924850-- -5%
How Healthy are Healthcare Companies: Complementary Research on Idera Pharma, Athersys Inc., Nevro Corp., Radius Health and OvaScience Inc.
13:40 (14/05) - Bron: PRN
For best results when printing this announcement, please click on the link
below:
http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20150514:enUK201505147878:1
NEW YORK, May 14, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several
important developing situations including Idera Pharmaceuticals, Inc. (NASDAQ:
IDRA), Athersys, Inc. (NASDAQ: ATHX), Nevro Corp. (NYSE: NVRO), Radius Health,
Inc. (NASDAQ: RDUS), and OvaScience, Inc. (NASDAQ: OVAS). Analysts Review
provides a single unified platform for investors' to hear about what matters -
proudly employing registered CFA research staff and rigorous compliance
procedures. The full research reports are being made available to the public for
informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links
below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into
your browser):
IDRA Research Report: (
http://get.analystsreview.com/pdf/?c=Idera%20Pharmaceuticals&d=14-May-2015&s=IDRA
),
ATHX Research Report: (
http://get.analystsreview.com/pdf/?c=Athersys&d=14-May-2015&s=ATHX ),
NVRO Research Report: (
http://get.analystsreview.com/pdf/?c=Nevro%20Corp&d=14-May-2015&s=NVRO ),
RDUS Research Report: (
http://get.analystsreview.com/pdf/?c=Radius%20Health&d=14-May-2015&s=RDUS ),
OVAS Research Report: (
http://get.analystsreview.com/pdf/?c=OvaScience&d=14-May-2015&s=OVAS ).
============
--
Analyst Update: Earnings Update, Regulatory Approval
U.S. stocks closed virtually flat on Wednesday, amid disappointing monthly
retail sales data. The Dow Jones Industrial Average fell 0.04%, to finish at
18,060.49, the S&P 500 edged down 0.03%, to 2,098.48, while the NASDAQ Composite
rose modestly by 0.11%, to end the session at 4,981.69. European stocks mostly
closed lower on Wednesday, despite positive economic growth data. Germany's
DAX 30 declined 1.05%, and France's CAC 40 slipped 0.26%. In contrast,
London's FTSE 100 closed 0.23% higher on Wednesday, mainly reflecting upbeat
unemployment data. Meanwhile, Asian markets were mixed on Wednesday, amid weaker
Chinese economic data. The Shanghai Composite and Hong Kong's Hang Seng were
both down on Wednesday, while Japan's Nikkei closed higher.
On May 11, 2015, Idera Pharmaceuticals, Inc. reported its financial and
operational results for Q1 FY15. Revenue rose to $34,000 in Q1 FY15 from
$3,000 in Q1 FY14. Net loss applicable to common stockholders for Q1 FY15 was
$12.5 million, or $0.12 per diluted share, compared to $9.1 million, or
$0.12 per diluted share, for the same period in 2014.
On May 11, 2015, Athersys, Inc. announced its Q1 FY15 results. Revenue rose by
3.4% to $0.73 million in Q1 FY15 from $0.71 million in Q1 FY14. R&D expenses
were $5.7 million for the first quarter of 2015 compared to $6.2 million for
the prior-year period.
On May 8, 2015, Nevro Corp., a medical device company that provides solutions
for the treatment of chronic pain, announced that it has received approval from
the United States Food and Drug Administration (FDA) for its Senza spinal cord
stimulation (SCS) system.
On May 6, 2015, Radius Health, Inc. announced its Q1 FY15 results. Net loss for
Q1 FY15 was $17.1 million, or $0.47 per share, as compared to a net loss of
$14.5 million, or $50.45 per share for Q1 FY14.
OvaScience reported its Q1 FY15 financial results on May 11, 2015. Net loss for
the quarter was $17.2 million, or $0.65 per share, as compared to net loss of
$7.8 million, or $0.41 per share, for the same period in 2014.
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to
leverage our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and analysis of
the complexities contained in each situation. That's where Analysts Review comes
in. We provide a single unified platform for investors' to hear about what
matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information
available, we have set ourselves apart as one of the premier online investor
communities.
--
Editor Note: This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a
best-effort basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider, represented by a
registered analyst has only reviewed the information provided by Analysts Review
in this article or report according to the procedures outlined by Analysts
Review. Analysts Review is not entitled to veto or interfere in the application
of such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.
Further Resources: For more information about this release including editorial
notes, compliance procedures and legal disclosures, please visit:
http://www.analystsreview.com/editors
CFA and Chartered Financial Analyst are registered trademarks owned by CFA
Institute.
SOURCE Analysts Review
Adam Redford
CONTACT PHONE: +1-800-632-0568
Copyright © 2015 PR Newswire Association, LLC. All Rights Reserved.
this stock is not for daytrayding for the moment
ATHX moving up a bit---1,34---+12%
Cord Blood America, Inc. Files -- 8-K
14:31 (08/05) - Bron: EDG
http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20150508:EDG_0001354488-15-002204
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The following Exhibits are furnished herewith:
Exhibit No. Description
99.1
Press Release dated May 8, 2015
Item 8.01 Other Events.
On May 8, 2015, the Company issued the Press Release attached as Exhibit 99.1 to this report. The information included in Exhibit 99.1 is considered to be "furnished" under the Securities Exchange Act of 1934.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements giving the Company’s expectations or predictions of future financial or business performance or conditions. Forward-looking statements are typically identified by words such as "believe," "expect," "anticipate," "intend," "target," "estimate," "continue," "positions," "prospects" or "potential," and future conditional verbs such as "will," "would," "should," "could" or "may," or by variations of such words or by similar expressions. These forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made and we assume no duty to update forward-looking statements. Actual results may differ materially from current projections.
Cord Blood America Reports 2015 First Quarter Financial Results and Results of Special Shareholder Meeting, Announces Annual General Meeting
14:30 (08/05) - Bron: PRN
For best results when printing this announcement, please click on the link
below:
http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20150508:LA02952:1
Revenue Increased 39%, EBITDA of $0.208 million
LAS VEGAS, May 8, 2015 /PRNewswire/ -- Cord Blood America, Inc.
(www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or the "Company")
today announced financial results for the quarter ended March 31, 2015 and the
results of the Special Shareholder Meeting.
Results of Special Shareholder Meeting:
* At the May 7th, 2015 special meeting, shareholders approved the increase in
authorized shares.
The Board of Directors set June 9, 2015 as the Record Date for the Company's
Annual General Meeting, To Be Held July 14, 2015, to Elect Directors, Ratify
Auditors and Approve Changes to the Company's Articles of Incorporation and
Bylaws.
First Quarter Highlights Include:
* Revenue increased 39.0% to $1.278 million from $0.920 million in the same
period of 2014.
* Recurring revenues increased approximately 7.0% for the three months ended
March 31, 2015 to $0.660 million compared to 2014 and now represent over 51%
of total revenue.
* EBITDA was $0.208 million compared to a loss of $.022 million in 2014.
Subsequent Event:
* On April 9, 2015 the Company announced a $0.724 million preferred equity
investment from Red Oak Partners LLC and affiliates (collectively "Red Oak").
* The proceeds of the Red Oak investment were used to pre-pay a portion of the
Tonaquint debt obligation. The Company's total debt outstanding is $1.410
million as of April 30, 2015.
David Sandberg, Chairman of Cord Blood America, Inc. stated, "With the approval
of the increase in authorized shares and the deleveraging of the balance sheet,
the Company now has the ability to invest in growth opportunities that it
previously was unable to capitalize on. We have also appointed Board committees
and approved committee charters, and we are progressing on other corporate
governance improvements. Lastly, Red Oak's investment has now automatically
converted into common shares equivalent to 29.98% ownership in the Company."
Joseph Vicente, President of Cord Blood America, Inc. commented, "This was a
strong quarter and we are pleased with the performance of the business. We are
excited about the future."
Results of Operations for the Three-Months March 31, 2015
For the three months ended March 31, 2015, total revenue increased to
approximately $1.278 million from $0.920 million, an increase of 39.0% over
the same period of 2014. Processing fees decreased by approximately 14% while
recurring storage fees and the procurement of birth tissue increased
approximately 7% and 494%, respectively, over the prior comparative three month
period. The Company remains focused on strategic growth which management expects
will provide sustainable operating cash flows and positive operating income.
Gross profit increased by approximately $0.226 million to $0.876 million for
the period ending March 31, 2015 from the prior year due to the increase in
revenue. Gross margin decreased from 70.7% to 68.5% year over year due to an
increased percentage of revenue associated with the procurement of birth tissue
which has a lower gross margin.
Administrative and selling expenses for the first quarter were $0.774 million
as compared to $0.806 million in 2014. These expenses are primarily related to
marketing/advertising, professional services, allocated facility related
expenses, wages for personnel, and depreciation and amortization.
Net loss was $0.209 million versus a net loss of $0.437 million in 2014.
EBITDA increased to $0.208 million from a loss of $0.022 million in 2014. In
the first quarter 2014 the Company incurred $154,471 in legal expenses
associated with the St. George and Tonaquint litigation which was settled in
2014.
Non-GAAP Measures
In addition to the GAAP financial measures set forth in this press release, the
Company has included the non-GAAP measurement EBITDA which presents operating
results on a basis adjusted for depreciation, amortization, interest expense and
taxes. The Company uses this non-GAAP measure as a key performance measure for
the purpose of evaluating performance internally. We also believe this non-GAAP
measure provides our investors with useful information regarding our operating
results. This non-GAAP measure is not intended to replace the presentation of
our financial results in accordance with GAAP. Use of the term EBITDA may differ
from similar measures reported by other companies.
About Cord Blood America, Inc.
Cord Blood America, Inc. is the parent company of CorCell Companies, Inc. which,
along with Cord Blood America, Inc., facilitates umbilical cord blood and cord
tissue stem cell processing and storage for expectant parents and their
children. Collected through a safe and non-invasive process, cord blood stem
cells offer a powerful and potentially life-saving resource for treating a
growing number of ailments, including cancer, leukemia, blood, and immune
disorders. To find out more about Cord Blood America, Inc. and CorCell
Companies, Inc., visit our websites: http://www.cordblood-america.com/ for
investor information and http://www.corcell.com/ for customer information.
Forward-Looking Statements
Some statements made in this press release are forward-looking statements, which
are made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. We use words such as "anticipate," "believe,"
"expect,'' "future," "intend," "plan," and similar expressions to identify
forward-looking statements. These statements including those related to the
growth of the industry, new stem cell treatments, and Cord Blood America's
performance, are only predictions and are subject to certain risks,
uncertainties and assumptions. Additional risks are identified and described in
the Company's public filings with the Securities and Exchange Commission.
Statements made herein are as of the date of this press release and should not
be relied upon as of any subsequent date. The Company's past performance is not
necessarily indicative of its future performance. The Company does not
undertake, and the Company specifically disclaims any obligation to update any
forward-looking statements to reflect occurrences, developments, events, or
circumstances after the date of such statement.
Investor Cameron Donahue
Contact:
Hayden IR
(651) 653-1854
cameron@haydenir.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cord-blood-america-reports-2015-first-quarter-financial-results-and-results-of-special-shareholder-meeting-announces-annual-general-meeting-300080191.html
SOURCE Cord Blood America, Inc.
Copyright © 2015 PR Newswire Association, LLC. All Rights Reserved.
Haha, not enough volume for that....
0039 x 0040
CBAI--volume 7604799--0.0038--+12%
shortselling is great for the moment....but...
1.33 ATHX
1.30 ATHX
yes, today a green day. ATHX
added a 1,03 today, not bad!
Cord Blood America, Inc. Files -- 8-K
12:12 (14/04) - Bron: EDG
http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20150414:EDG_0001354488-15-001723
Item 5.02 Compensatory Arrangements of Certain Officers.
Effective April 9, 2015, as part of the transaction with Red Oak, the Company entered into an Amendment to Executive Employment Agreement with Joseph R. Vicente, the Company’s President and Chairman of the Board, amending Mr. Vicente’s January 1, 2015 Executive Employment Agreement, as well as an Amendment to Executive Employment Agreement with Stephen Morgan, the Company’s Vice President, General Counsel and Secretary, amending Mr. Morgan’s April 1, 2015 employment agreement such that Mr. Vicente and Mr. Morgan no longer have the option, in their sole discretion, to receive their salary and bonus amounts in the form of Company stock, rather than cash.
Item 1.01 Entry Into a Material Definitive Agreement.
On April 9, 2015, Cord Blood America, Inc. (the "Company") executed a Preferred Stock Purchase Agreement (the "Purchase Agreement") and a Stockholder Agreement with Red Oak Fund LP, Red Oak Long Fund, LP and Pinnacle Opportunities Fund, LP (collectively the "Purchasers" or "Red Oak").
Pursuant to the Purchase Agreement, the Purchasers are to deliver to the Company, at Closing (defined in the Purchase Agreement), $724,000 (the "Purchase Price"), and the Company is to deliver to the Purchasers 724,000 shares of Series A Convertible Preferred Stock (the "Preferred Stock"). The terms of the Preferred Stock are set forth in Articles of Amendment to Articles of Incorporation of the Company ("Articles of Amendment") that were designated by the Board of Directors of the Company on April 9, 2015 and are filed as an Exhibit to this Current Report.
As set forth in the Articles of Amendment, the Preferred Stock shall be convertible into common stock of the Company at the "Conversion Rate," where each holder of Preferred Stock shall be entitled to common stock in accordance with the number of shares of Preferred Stock they hold divided by the total shares of Preferred Stock outstanding, 724,000 shares, multiplied by the "Maximum Common Converted Share Number," which is 29.9793% of the outstanding shares of the Company on a fully diluted and converted basis assuming the conversion of all convertible securities, including the conversion of the Preferred Stock. The Preferred Stock shall not be converted until such time as there are sufficient authorized common stock shares, which are not reserved for other purposes, in order that all of the Preferred Stock can be converted to common shares. When there are sufficient such shares, all of the Preferred Stock shall automatically be converted to common stock at the Conversion Rate.
Further pursuant to the Articles of Amendment, while Preferred Stock is outstanding, the holders of Preferred Stock, voting exclusively and as a separate class, are entitled to elect three (3) Directors to the Board of Directors of the Company (the "Series A Directors"). The Series A Directors may be removed without cause only by a vote of the holders of the Preferred Stock. As set forth in the Purchase Agreement, the Board of Directors shall consist of a total of six (6) Directors, and under the Articles of Amendment, in the event of a Deadlock Resolution Event (defined in the Articles of Amendment), the holder of a majority of the Preferred Stock shall propose three (3) potential Independent Qualified Directors (defined in the Articles of Amendment), and the Board of the Company shall select one of them to serve as the Independent Qualified Director, in order to vote to break a deadlock.
In addition, on any matter presented to the stockholders for vote, the Preferred Stock shall vote as a class with the holders of common stock, and each share of Preferred Stock shall entitle the holder thereof to such number of votes as if the Preferred Stock were converted to common stock at the Conversion Rate.
In the event of a Deemed Liquidation Event (defined in the Articles of Amendment), the Purchasers are entitled to receive the greater of: i) the Purchase Price, plus any dividends declared but unpaid thereon; and ii) the amount the Purchasers would be entitled to receive if the Preferred Stock were converted to common stock of the Company prior to such Deemed Liquidation Event.
Under the Stockholder Agreement, in the event of a sale or transfer of more than fifty percent (50%) of the assets or shares outstanding of the Company or any merger (or similar transaction) that requires approval of the Company’s stockholders and results in a change of control of the Company where (i) the proposed acquirer is Red Oak or any entity or group in which Red Oak and/or David Sandberg has 10% of more of the economic interest, (ii) within six months prior to the date of a stockholder vote to approve such a transaction a Red Oak employee, partner, member, manager or officer is or has served as a member of the Board of Directors of the Company, and (iii) Red Oak is the largest shareholder at the time of the record date to approve such a transaction, then Red Oak shall vote any shares in excess of the number of shares held by the next largest stockholder, other than Red Oak, pro rata in accordance with the aggregate voting of Company shares held by parties other than Red Oak or any entity or group which includes Red Oak.
Collectively, the Purchase Agreement, Stockholder Agreement and Articles of Amendment are sometimes referred to herein as the "Transaction Documents".
The Transaction Documents contain representations and warranties of the Company and the Purchasers that are customary for transactions of this kind.
The foregoing is only a summary of the terms of the transaction between the Company and the Purchasers. You are urged to read each of the Transaction Documents, which are attached as Exhibits to this Current Report and incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The following Exhibits are furnished herewith:
Exhibit No. Description
10.1 Preferred Stock Purchase Agreement
10.2 Stockholder Agreement
10.3 Articles of Amendment to Articles of Incorporation of Cord Blood America, Inc.
10.4
Amendment to Executive Employment Agreement of Joseph Vicente
10.5
Amendment to Executive Employment Agreement of Stephen
Wait and see...run coming..CBAI
CBAI--volume 22179791---0.0046--- +15%
Cord Blood America Announces Equity Investment by Red Oak Partners, LLC for Purposes of Debt Retirement and to Focus on Forward Growth, Adjourns Special Meeting to May 7th
14:45 (10/04) - Bron: PRN
For best results when printing this announcement, please click on the link
below:
http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20150410:LA77073:1
Cord Blood America Announces Equity Investment by Red Oak Partners, LLC for Purposes of Debt Retirement and to Focus on Forward Growth, Adjourns Special Meeting to May 7th
14:45 (10/04) - Bron: PRN
For best results when printing this announcement, please click on the link
below:
http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20150410:LA77073:1
Cord Blood America Announces Equity Investment by Red Oak Partners, LLC for Purposes of Debt Retirement and to Focus on Forward Growth, Adjourns Special Meeting to May 7th
14:45 (10/04) - Bron: PRN
For best results when printing this announcement, please click on the link
below:
http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20150410:LA77073:1
Cord Blood America Announces Equity Investment by Red Oak Partners, LLC for Purposes of Debt Retirement and to Focus on Forward Growth, Adjourns Special Meeting to May 7th
14:45 (10/04) - Bron: PRN
For best results when printing this announcement, please click on the link
below:
http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20150410:LA77073:1
LAS VEGAS, April 10, 2015 /PRNewswire/ -- Cord Blood America, Inc.
(www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or the "Company")
today announced it has executed a purchase agreement for the sale of $0.724
million preferred equity investment funded by Red Oak Partners, LLC and its
affiliates ("Red Oak"). All proceeds shall be used towards retiring debt owed
to Tonaquint, Inc.
Joseph Vicente, President of Cord Blood America, Inc. commented "In December
2014 we settled litigation with Tonaquint, Inc. which was a positive but
resulted in monthly amortization and interest payments in excess of our
estimated cash generation. Accordingly, the Company was weakly positioned and
could not seize upon the sizable growth and market opportunities available to
us. Red Oak's investment stabilizes our organization and allows us to
immediately focus on growth endeavors, including taking market share from our
competitors. We are adjourning the April 10th special meeting to May 7th in
order to allow shareholders reasonable time to digest this investment and make
an informed decision.
Red Oak has had meaningful dialogue and iterations of term sheets prior to and
during the Tonaquint litigation as well as after the settlement was announced
and brings significant value across M&A, financing, and corporate governance.
Red Oak's managing member (David Sandberg) and its team have strong public
company experience and a track record of success, and we plan to leverage their
skills to help us grow shareholder value. As part of their investment, the
Board will consist of a majority of Directors independent from management.
Stated David Sandberg, "With a more stabilized balance sheet, CBAI is well
positioned to pursue a sensible yet meaningful growth strategy. We believe this
best serves shareholders' interests and we are already working to compile and
reach out to M&A targets. CBAI's excess storage capacity coupled with a less
constrained marketing budget allows for a real opportunity to grow its business
both organically and via acquisitions with improved margins and earnings to the
bottom line. In addition to focusing on growth, the Board will be populated
with new Directors independent from management and we expect to implement
shareholder friendly changes to CBAI's Charter and Bylaws as well as to call an
annual meeting for Director Elections and other business (as is proposed). We
expect CBAI to announce an annual meeting date shortly after the May 7th
special meeting.
Continued Mr. Vicente, "As many of you may know, Cryo-Cell International, one of
our competitors, has publicly announced over the past 30 days (through a series
of filings) their ownership stake in CBAI and stated its intention to nominate a
slate of directors for election and, if successful, to 'explore various
alternatives, including the potential for a merger between CBAI and Cryo-Cell,
with Cryo-Cell as the surviving entity.' We are aware we have been in a weak
position given our balance sheet, and some - like Cryo-Cell - are seeking to
take advantage of this. Red Oak has a demonstrated history of good governance
and going out of their way to protect the rights of all shareholders, not just
their own interests. While it is important to provide balance sheet relief via
Red Oak's investment, we would only enter into a transaction that is in the
best interest of all shareholders and provides the greatest opportunity to
create future value for all shareholders. As part of this investment agreement
with Red Oak, should Red Oak seek to take CBAI private then any voting rights
it holds in excess of what the second largest shareholder holds shall be voted
along with the consensus outside of Red Oak. Effectively their excess voting
rights can work against them if the majority of other holders don't support such
a deal."
"In closing, we are confident that the platform, both operationally and
financially, is at its strongest point in the Company's operating history. With
the Company's past issues largely resolved and a new and experienced partner in
place, we expect to produce significantly improved long term shareholder returns
and be better able to compete in our industry - including against Cryo-Cell and
others - as we move ahead."
About Cord Blood America
Cord Blood America, Inc. is the parent company of CorCell Companies, Inc. which,
along with Cord Blood America, Inc., facilitates umbilical cord blood and cord
tissue stem cell processing and storage for expectant parents and their
children. Collected through a safe and non-invasive process, cord blood stem
cells offer a powerful and potentially life-saving resource for treating a
growing number of ailments, including cancer, leukemia, blood, and immune
disorders. To find out more about Cord Blood America, Inc. and CorCell
Companies, Inc., visit our websites: http://www.cordblood-america.com/ for
investor information and http://www.corcell.com/ for customer information.
Forward-Looking Statements
Some statements made in this press release are forward-looking statements, which
are made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. We use words such as "anticipate," "believe,"
"expect,'' "future," "intend," "plan," and similar expressions to identify
forward-looking statements. These statements including those related to the
growth of the industry, new stem cell treatments, and Cord Blood America's
performance, are only predictions and are subject to certain risks,
uncertainties and assumptions. Additional risks are identified and described in
the Company's public filings with the Securities and Exchange Commission.
Statements made herein are as of the date of this press release and should not
be relied upon as of any subsequent date. The Company's past performance is not
necessarily indicative of its future performance. The Company does not
undertake, and the Company specifically disclaims any obligation to update any
forward-looking statements to reflect occurrences, developments, events, or
circumstances after the date of such statement.
Investor Contact: Cameron Donahue
Hayden IR
(651) 653-1854
cameron@haydenir.com
Web Site: http://www.cordblood-america.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cord-blood-america-announces-equity-investment-by-red-oak-partners-llc-for-purposes-of-debt-retirement-and-to-focus-on-forward-growth-adjourns-special-meeting-to-may-7th-300063995.html
SOURCE Cord Blood America, Inc.
Copyright © 2015 PR Newswire Association, LLC. All Rights Reserved.